Complement Therapeutics Complement Therapeutics Complement Therapeutics

Complement Therapeutics

Developing the next generation of complement medicines

Complement Therapeutics (CTx), a spin out of the University of Manchester founded in 2021, aims to transform the treatment of complement-mediated conditions by developing novel therapies in ophthalmology and beyond. The ground-breaking research conducted by the founders of Complement Therapeutics has an initial key-focus on establishing a gene therapy for dry AMD with an ongoing effort to broaden the pipeline further.

Life Sciences

Visit website

Investment  details

Entry

2023

Staff

Location

Germany

With a potentially highly differentiated lead asset combined with a precision medicine approach, we are excited by the opportunity to further develop CTx001 for the treatment of GA through to the clinic. The support of this broad syndicate enables us to generate additional data demonstrating CTx001’s unique and differentiated mechanism of action, with the potential to transform the treatment landscape in geographic atrophy.

Dr. Rafiq Hasan

CEO

Partnership Gimv

Gimv’s investment in CTx is a key example of our Life Sciences strategy at its core, which is to invest in companies where cutting-edge science could lead to a potential paradigm shift in the treatment and lives of patients. Geographic atrophy (late dry age-related macular degeneration) is the leading cause of irreversible loss of visual function, affecting millions of individuals worldwide. CTx is a key example of an investment whereby Gimv is proud to have built a strong investor syndicate that supports a company with the potential to positively impact human health.